Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Dynavax Technologies Corporation is active in the Biotechnology & Pharmaceuticals technology area and currently has 5 pending office actions. These 5 actions are assigned to 5 distinct examiners, meaning that every pending matter is being reviewed by a unique individual. This distribution across 5 distinct examiners suggests that the company is receiving a range of examiner feedback on its biotechnology innovations.
The prosecution of these 5 pending office actions is concentrated within 4 distinct art units. This concentration is notable because it shows that while the examiners are all different, they are working within 4 technical groups. This suggests that the company's 5 pending matters are technically related enough to be funneled into 4 art units, even though 5 distinct examiners are involved in the process.
BLUMEL, BENJAMIN P is the busiest examiner for Dynavax Technologies Corporation, with 1 pending office action. Since the 5 pending office actions are split among 5 distinct examiners, each examiner is responsible for 1 action. This split indicates that no single examiner, including BLUMEL, BENJAMIN P, holds a large portion of the current workload. The pending actions are thus subject to independent review processes within the 4 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838947 | IMMUNOGENIC COMPOSITIONS COMPRISING A RECOMBINANT NEURAMINIDASE AND CpG OLIGONUCLEOTIDE ADJUVANT, AND USES THEREOF | BLUMEL, BENJAMIN P | — |
| 18723407 | IMMUNOGENICITY OF A CPG-ADJUVANTED HERPES ZOSTER VACCINE | SALVOZA, M FRANCO G | — |
| 18592811 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) | FOLEY, SHANON A | — |
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1672 | 1 |
| 1691 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838947 | IMMUNOGENIC COMPOSITIONS COMPRISING A RECOMBINANT NEURAMINIDASE AND CpG OLIGONUCLEOTIDE ADJUVANT, AND USES THEREOF | BLUMEL, BENJAMIN P | 1671 | §103DP | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18723407 | IMMUNOGENICITY OF A CPG-ADJUVANTED HERPES ZOSTER VACCINE | SALVOZA, M FRANCO G | 1672 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18629809 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18592811 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) | FOLEY, SHANON A | 1671 | §103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDynavax Technologies Corporation has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Benjamin P Blumel has the most, with 1 of Dynavax Technologies Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
